Fate Therapeutics Inc (FATE)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Fate Therapeutics Inc (FATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013976
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidates. Its immuno-oncology product candidates include adaptive NK, pluripotent cell-derived cancer immunotherapies, and engineered CAR and TCR T- cell immunotherapies. Its products are derived from pluripotent cells. Fate Therapeutics uses ex vivo cell programming approach to include cell-surface proteins, rapid and supra-physiologic activation or inhibition of therapeutically-relevant genes, and to regulate the therapeutic function. The company’s immuno-regulatory cellular therapies promote immune system homeostasis for patients undergoing hematopoietic cell transplantation and immune disorders. Fate Therapeutics is headquartered in San Diego, California, the US.

Fate Therapeutics Inc (FATE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Fate Therapeutics Raises US$20 Million In Venture financing 12
Fate Therapeutics Raises US$9.2 Million In Venture financing 13
Fate Therapeutics Secures Venture Financing 14
Fate Therapeutics Secures US$1 Million In Venture Financing 16
Fate Therapeutics Raises US$36 Million In Series B Financing 17
Partnerships 19
Fate Therapeutics Enters into Agreement with Memorial Sloan Kettering Cancer Center 19
Fate Therapeutics Enters into Research Agreement with Regents of the University of Minnesota 20
Fate Therapeutics Enters into Research Agreement with Boston Children’s Hospital 21
Licensing Agreements 22
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 22
Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 24
Equity Offering 25
Fate Therapeutics to Raise Funds through Public Offering of Shares 25
Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 26
Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 28
Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 29
Fate Therapeutics to Raise USD10.3 Million in Private Placement of Shares 30
Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 31
Fate Therapeutics Completes IPO For US$46 Million 33
Fate Therapeutics Inc – Key Competitors 34
Fate Therapeutics Inc – Key Employees 35
Fate Therapeutics Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Nov 01, 2017: Fate Therapeutics Reports Third Quarter 2017 Financial Results 37
Aug 14, 2017: Fate Therapeutics Reports Second Quarter 2017 Financial Results 40
May 15, 2017: Fate Therapeutics Reports First Quarter 2017 Financial Results 42
Mar 16, 2017: Fate Therapeutics Reports Fourth Quarter 2016 Financial Results 44
Nov 07, 2016: Fate Therapeutics Reports Third Quarter 2016 Financial Results 46
Aug 08, 2016: Fate Therapeutics Reports Second Quarter 2016 Financial Results 48
May 09, 2016: Fate Therapeutics Reports First Quarter 2016 Financial Results 50
Mar 03, 2016: Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results 51
Corporate Communications 53
Sep 14, 2017: Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development 53
May 17, 2016: Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer 54
Product Approvals 55
Sep 26, 2016: Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune in Allogeneic Hematopoietic Cell Transplantation 55
Jan 26, 2016: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection 56
Clinical Trials 57
Jun 11, 2016: Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases 57
May 16, 2016: Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy 58
Feb 21, 2016: Fate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fate Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Fate Therapeutics Raises US$20 Million In Venture financing 12
Fate Therapeutics Raises US$9.2 Million In Venture financing 13
Fate Therapeutics Secures Venture Financing 14
Fate Therapeutics Secures US$1 Million In Venture Financing 16
Fate Therapeutics Raises US$36 Million In Series B Financing 17
Fate Therapeutics Enters into Agreement with Memorial Sloan Kettering Cancer Center 19
Fate Therapeutics Enters into Research Agreement with Regents of the University of Minnesota 20
Fate Therapeutics Enters into Research Agreement with Boston Children's Hospital 21
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 22
Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 24
Fate Therapeutics to Raise Funds through Public Offering of Shares 25
Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 26
Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 28
Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 29
Fate Therapeutics to Raise USD10.3 Million in Private Placement of Shares 30
Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 31
Fate Therapeutics Completes IPO For US$46 Million 33
Fate Therapeutics Inc, Key Competitors 34
Fate Therapeutics Inc, Key Employees 35
Fate Therapeutics Inc, Subsidiaries 36

★海外企業調査レポート[Fate Therapeutics Inc (FATE)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lonrho Ltd:企業のM&A・事業提携・投資動向
    Lonrho Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lonrho Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Calgary Scientific Inc:医療機器:M&Aディール及び事業提携情報
    Summary Calgary Scientific Inc (Calgary Scientific) is a medical imaging company that provides research and diagnostic technologies for the medical industry. The company offers ResolutionMD, is a zero-footprint enterprise viewing platform, which is installed in healthcare facilities and used to view …
  • Vienna Insurance Group AG:企業のM&A・事業提携・投資動向
    Vienna Insurance Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vienna Insurance Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • T3D Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary T3D Therapeutics Inc (T3D) is a developer of solutions for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The company’s pipeline product include T3D-959, an optimal disease remedial therapeutic for the treatment of Alzheimer’s disease. It provides a potential to improve …
  • MEAG Munich Ergo AssetManagement GmbH:電力:M&Aディール及び事業提携情報
    Summary MEAG Munich Ergo AssetManagement GmbH (MEAG Munich), a subsidiary of Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft (Munich Re) is an asset management company that manages assets of Munich Re and ERGO Insurance Group and its affiliates. The company offers services such as asset …
  • Orion Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Orion Health Inc (Orion) is a healthcare technology company that offers software solutions. The company designs healthcare software for hospitals and health systems. Its products comprise electronic health record, rhapsody integration engine, hospital information system and symphonia messagi …
  • Autotelic Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Autotelic Inc (Autotelic) is a therapeutic drug monitoring company that develops novel treatments using its therapeutic drug monitoring (TDM) services. The company's pipeline products include devices to improve safety and efficacy of COX-2 inhibitors, paclitaxel nanomedicine, TGF-beta inhibi …
  • Aabar Investments:企業の戦略的SWOT分析
    Aabar Investments - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Pfizer Ltd India (PFIZER):企業の財務・戦略的SWOT分析
    Summary Pfizer Ltd India (Pfizer India), a subsidiary of Pfizer Inc, is a pharmaceutical company that develops medicines for brain disorders. The company’s products portfolio comprises of anti-allergics, anti-diabetics, anti-histamines, anti-infectives, anti-parasitics, drugs for cardiovascular and …
  • I Grandi Viaggi Spa
    I Grandi Viaggi Spa - Strategy, SWOT and Corporate Finance Report Summary I Grandi Viaggi Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Paychex, Inc.:企業の戦略・SWOT・財務情報
    Paychex, Inc. - Strategy, SWOT and Corporate Finance Report Summary Paychex, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Klepierre SA:企業のM&A・事業提携・投資動向
    Klepierre SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Klepierre SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Exonate Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Exonate Ltd (Exonate) is a biopharmaceutical company that discovers and develops small molecule drugs which modulates the alternative mRNA splicing for the treatment of unmet medical needs. The comany's alternative mRNA splicing is modulated in disease states that results in the pathological …
  • HCA Healthcare, Inc.:企業の戦略・SWOT・財務分析
    HCA Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report Summary HCA Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Skyworks Solutions Inc (SWKS):企業の財務・戦略的SWOT分析
    Skyworks Solutions Inc (SWKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Cerus Energy Group Ltd (CEA):石油・ガス:M&Aディール及び事業提携情報
    Summary Cerus Energy Group Ltd (Cerus Energy), formerly Petrostar Petroleum Corp is an oil and gas company that produces methanol, DME, and petroleum and natural gas. The company offers deep well disposal, storage and terminalling services, and well management services. Its well management services …
  • Lebara Group:企業の戦略的SWOT分析
    Lebara Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Institute for Translational Vaccinology:製薬・医療:M&Aディール及び事業提携情報
    Summary Institute for Translational Vaccinology (Intravacc) is a nonprofit research and development organization that concentrates on the development of vaccines. The organization’s services include technology transfer, exploratory and clinical research and regulatory support. It also provides novel …
  • Arab Petroleum Investments Corp:企業の戦略的SWOT分析
    Arab Petroleum Investments Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Orbotech Ltd. (ORBK):企業の財務・戦略的SWOT分析
    Orbotech Ltd. (ORBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆